Merck's experimental oral pill enlicitide slashed LDL cholesterol by 58.2% in a Phase 3 trial of 2,909 patients, results published March 21 in The New England Journal of Medicine show. The drug, a PCSK9 inhibitor taken once daily, achieved reductions previously only possible with expensive injectable therapies like Repatha and Praluent.

"These reductions in LDL cholesterol are the most we have ever achieved with an oral drug by far since the development of statins," said lead researcher Dr. Ann Marie Navar of UT Southwestern Medical Center. The pill also significantly cut other cardiovascular risk markers, including apolipoprotein B by 50.3% and lipoprotein(a) by 28.2%.

Safety data from the CORALreef Lipids trial were encouraging — adverse event rates with enlicitide were comparable to placebo, with only 3.1% of patients discontinuing due to side effects versus 4.1% on placebo. A separate trial is now underway to determine whether these cholesterol reductions translate into fewer heart attacks and strokes.